Antibiotics play a crucial role in modern medicine and without them many treatments and procedures (for example in cancer care, organ transplantation and childbirth) carry a significantly higher risk of complication or failure. However, the increasing resistance of bacterial pathogens to antibiotics - Antimicrobial Resistance (AMR) - undermines the efficacy of these treatments and jeopardizes the benefits of modern healthcare, posing grave risks to vulnerable patient groups.
The world urgently needs Research & Development (R&D) to develop novel and innovative antibiotics that would not only safeguard the advance of medicine, but further provide value by decreasing the selection pressure on established antibiotics.
We stand at a pivotal moment to address the pressing health, economic, and societal issues of AMR. Public and private partners are facing the triple challenge of AMR: fostering innovation and viable markets for new, life-saving treatments and diagnostics, ensuring equitable access to safe and effective antibiotics, and the need for stewardship in use. Investment in science, technology, engineering and mathematics (STEM) education will be critical to build the AMR R&D workforce for the future.
Acknowledging that innovation is essential to addressing AMR, and drawing on the anticipated discussions related to the Political Declaration on AMR this session aims to explore real-world solutions in policy, funding and cross-sector collaboration to accelerate the discovery and global supply of groundbreaking antibiotics.
Hosts:
Global AMR R&D Hub
Roche
Moderators:
Shiulie Ghosh
Journalist and TV Anchor | United Kingdom
Speakers:
Dr. Khaled Abdel-Ghaffar
Deputy Prime Minister for Human Development and Minister of Health and Population | Egypt
Dr. Cary Adams
Union for International Cancer Control (UICC) | CEO | Switzerland
Prof. Dr. Sabiha Essack
University of Kwazulu-Natal | South African Research Chair in Antibiotic Resistance & One Health | South Africa
Dr. Malin Grape
Ministry of Health and Social Affairs | Ambassador on Antimicrobial Resistance | Sweden
Dr. Michael Lobritz
Roche Pharma Research & Early Development (pRED) | Infectious Diseases Therapeutic Area | VP and Global Head | Switzerland
Dr. Elmar Nimmesgern
European Commission | DG Research & Innovation | Policy Officer
Dr. Lesley Ogilvie
Global AMR R&D Hub | Secretariat | Director | Germany
Antibiotics play a crucial role in modern medicine and without them many treatments and procedures (for example in cancer care, organ transplantation and childbirth) carry a significantly higher risk of complication or failure. However, the increasing resistance of bacterial pathogens to antibiotics - Antimicrobial Resistance (AMR) - undermines the efficacy of these treatments and jeopardizes the benefits of modern healthcare, posing grave risks to vulnerable patient groups.
The world urgently needs Research & Development (R&D) to develop novel and innovative antibiotics that would not only safeguard the advance of medicine, but further provide value by decreasing the selection pressure on established antibiotics.
We stand at a pivotal moment to address the pressing health, economic, and societal issues of AMR. Public and private partners are facing the triple challenge of AMR: fostering innovation and viable markets for new, life-saving treatments and diagnostics, ensuring equitable access to safe and effective antibiotics, and the need for stewardship in use. Investment in science, technology, engineering and mathematics (STEM) education will be critical to build the AMR R&D workforce for the future.
Acknowledging that innovation is essential to addressing AMR, and drawing on the anticipated discussions related to the Political Declaration on AMR this session aims to explore real-world solutions in policy, funding and cross-sector collaboration to accelerate the discovery and global supply of groundbreaking antibiotics.
Hosts:
Global AMR R&D Hub
Roche
Moderators:
Shiulie Ghosh
Journalist and TV Anchor | United Kingdom
Speakers:
Dr. Khaled Abdel-Ghaffar
Deputy Prime Minister for Human Development and Minister of Health and Population | Egypt
Dr. Cary Adams
Union for International Cancer Control (UICC) | CEO | Switzerland
Prof. Dr. Sabiha Essack
University of Kwazulu-Natal | South African Research Chair in Antibiotic Resistance & One Health | South Africa
Dr. Malin Grape
Ministry of Health and Social Affairs | Ambassador on Antimicrobial Resistance | Sweden
Dr. Michael Lobritz
Roche Pharma Research & Early Development (pRED) | Infectious Diseases Therapeutic Area | VP and Global Head | Switzerland
Dr. Elmar Nimmesgern
European Commission | DG Research & Innovation | Policy Officer
Dr. Lesley Ogilvie
Global AMR R&D Hub | Secretariat | Director | Germany
Wir nutzen Cookies auf unserer Website. Einige von ihnen sind essenziell für den Betrieb der Seite, während andere uns helfen, diese Website und die Nutzererfahrung zu verbessern (Tracking Cookies). Sie können selbst entscheiden, ob Sie die Cookies zulassen möchten. Bitte beachten Sie, dass bei einer Ablehnung womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen.
DE 
EN 
